UNC2025

UNC2025 is a potent, ATP-competitive and highly orally active Mer/Flt3 inhibitor with IC50 values of 0.74 nM and 0.8 nM, respectively. UNC2025 is >45-fold selectivity for MERTK relative to Axl (IC50= 122 nM; Ki = 13.3 nM) . UNC2025 exhibits an excellent PK properties, and can be used for the investigation of acute leukemia[1].

Product Specifications

CAS Number

[1429881-91-3]

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

FLT3

Type

Reference compound

Related Pathways

Protein Tyrosine Kinase/RTK

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/UNC2025.html

Concentration

10mM

Purity

99.92

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

CN1CCN(CC2=CC=C(C3=CN([C@@H]4CC[C@@H](O)CC4)C5=NC(NCCCC)=NC=C53)C=C2)CC1

Molecular Formula

C28H40N6O

Molecular Weight

476.66

Precautions

H302, H315, H319, H335

References & Citations

[1]Zhang W, et al. UNC2025, a Potent and Orally Bioavailable MER/FLT3 Dual Inhibitor. J Med Chem. 2014 Aug 28;57 (16) :7031-41.|[2]DeRyckere D, et al. UNC2025, a MERTK Small-Molecule Inhibitor, Is Therapeutically Effective Alone and in Combination with CL14377 in Leukemia Models.Clin Cancer Res. 2017 Mar 15;23 (6) :1481-1492.